The FDA has approved VISIQ, an ultra mobile ultrasound system designed for greater mobility, manufactured by Philips.
The U.S. Food and Drug Administration (FDA) has given 510(k) clearance to the VISIQ ultrasound system by Philips.
The ultrasound system is heralded by Philips as being ultra mobile, and combines “greater mobility, performance and simplicity into a single miniaturized solution,” according to a release. The mobile option is an effort to increase access to quality diagnostic scans for more OB patients, and to provide a solution that is easily transported with a long battery life.
The VISIQ system features a transducer that fits comfortably in the user’s hand and was manufactured using advances in miniaturization to integrate a sophisticated broadband microdigital beam former and powerful acquisition module, the release said. The system is targeted for OB and abdominal applications.
The transducer is connected to a tablet display with touch-screen gestures. The tablet allows users to capture images, take measurements and share data, the release said. The system also offers many of the automatic image optimization features found on Philips’ EPIQ system and includes built in Wi-Fi for DICOM data transfer to hospital or cloud-based PACS.
[[{"type":"media","view_mode":"media_crop","fid":"26034","attributes":{"alt":"Philips VISIQ","class":"media-image media-image-right","id":"media_crop_5484037953428","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2468","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 1px; border-style: solid; line-height: 1.538em; height: 133px; width: 200px; float: right;","title":" ","typeof":"foaf:Image"}}]]
"VISIQ marks a new vision in ultrasound for Philips by allowing physicians to perform on-the-spot diagnostic scans, limiting the need for patients to go to multiple locations or schedule return visits," Gene Saragnese, CEO, Imaging Systems, Philips Healthcare, said in the release.
VISIQ is also commercially available in China, East Africa, France, Germany and India.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.